Syneron Medical Ltd (ELOS)

[wiltonio]

Sand Grove Capital Management LLP has filed a new activist 13D, reporting 5.2% ownership in $ELOS - https://fintel.io/so/us/elos

[surf1944]

9:08AM Syneron Medical UltraShape Contour I System met the primary hypothesis for clinically significant circumference reduction (ELOS) 9.00 : Co has completed the multi-site clinical study for the UltraShape Contour I System for non-invasive abdominal circumferential reduction. The results successfully met the primary hypothesis for clinically significant circumference reduction. Furthermore, the results demonstrated progressive improvement over time in circumference reduction, beginning after the first treatment session. No serious adverse events related to the device were reported. The treatment was administered without the need for anesthetic and was well tolerated by patients. Circumference Reduction achieved exceeded FDA-specified margin by over 50% and demonstrates significant abdominal circumference reduction with a high degree of statistical significance.

[Penny Roger$]

~ Thursday! $ELOS ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ELOS ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ELOS&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ELOS&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ELOS
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ELOS#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ELOS+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ELOS
Finviz: http://finviz.com/quote.ashx?t=ELOS
~ BusyStock: http://busystock.com/i.php?s=ELOS&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ELOS >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[mlkrborn]

http://seekingalpha.com/article/253216-syneron-medical-ceo-discusses-q4-2010-results-earnings-call-transcript?source=yahoo

[mlkrborn]

Better than expected earnings report moved it up.

[midastouch017]

Syneron to develop home-use line with P&G
Syneron will lead R&D and production; Procter & Gamble will handle marketing and distribution.
Tali Tsipori 27 Feb 07 18:44
For a long time, especially at investors conferences, Syneron Medical Ltd. (Nasdaq: ELOS) has reiterated that one of its main growth engines would be home-use electro-optical synergy (ELOS) technology-based skin treatment products. The company today took another important step towards this goal with the announcement it had signed a an exclusive joint development and supply agreement with The Procter & Gamble Company (NYSE:PG) for the commercialization of patented, ELOS-based, home-use devices and compositions for the enhancement of skin appearance through the treatment of fine lines, wrinkles, age and sun spots, and cellulite.
Syneron, founded by chairman Dr. Shimon Eckhouse, is traded at a market cap of $688 million. The share rose 8% when the market opened today. Procter & Gamble, which is on the Dow Jones Index, has a market cap of over $200 billion.

Syneron said, “P&G selected ELOS technology as its preferred, non-invasive, energy-based solution for home-use aesthetic treatments in this field. Under the terms of the agreement Syneron will lead the research, development and manufacturing while P&G will focus on the development of the compositions, marketing, and distribution. The home-use devices will be marketed under the P&G family of skin care products and will be co-branded with Syneron's elos technology. P&G and Syneron plan further collaboration that could lead to commercializing additional products in the future.”

Published by Globes [online], Israel business news - www.globes.co.il - on February 27, 2007

[midastouch017]

Syneron gets beauty treatment
Commentators, and investors, are beginning to see that the aesthetic medicine device company's warts were temporary.
Shlomo Greenberg
The Motley Fool, a business and investment news site which is targeted at the more intelligent among us yet is still highly popular, recently chose Syneron Medical Ltd. (Nasdaq: ELOS) as its best small cap stock for 2007. And here was I, thinking for a moment that Yokne'am had been abandoned by the wayside. Syneron is certainly one of the best stocks around.
The interesting thing about the review, which was written by Matt Koppenheffer, is that it begins with an explanation about Syneron and why it chose the word ‘ELOS’ as its ticker. This implies that Koppenheffer thinks that Motley Fool’s readers have not heard of the company. “The area of aesthetic tweaking is big business,” he says, “and Syneron hopes to bring that fantasy in a quicker, easier and less painful way.” But then Koppenheffer gets down to the more serious financial data on the company, which leads him to conclude that if things continue at the present pace, the stock will be extremely attractive, even without another big breakthrough in aesthetic devices. This is why he has chosen it as his best small cap stock for 2007.

Articles of this kind on sites like the Motley Fool are of the utmost importance for Israeli companies. There are not many companies that have $160 million in cash, a 43% operating margin, and a historical multiple of 16.6, and this is why Koppenheffer considers Syneron such an attractive stock. What has happened, he thinks, (and I entirely agree with him) is that after peaking at $46, the stock made a sharp drop after it increased its sales and marketing spending, and then missed its earnings per share projections for the fourth quarter of 2005 and first quarter of 2006. In instances such as these, Wall Street hits hard, and does not forgive in a hurry. Koppenheffer believes that Syneron will continue to increase its sales and marketing spending in 2007 but should also start to benefit from the increased spending in 2006. Once Wall Street has forgiven it, the stock will accrue a premium.

Koppenheffer wrote a previous review of Syneron back in February, when the stock fell 40% after peaking at $46.2 in December. He said then that to dump Syneron solely because it posted lower growth over two quarters would not be a wise move. But Wall Street and James Cramer’s loose tongue are stronger than reality. Having tired of Syneron, Cramer switched to another aesthetic treatment stock, and the analysts - whether under the influence of Cramer or not - began to give the company the cold shoulder.

Despite Koppenheffer’s recommendations, Syneron continued to fall over the next five months, and by the end of July it had lost a further 30%. After starting December at $46.2, the company found itself at $19 at the beginning of August. Despite its recent gains, I feel that the current price - $24 - is very attractive (a consensus multiple of 12 for 2007, which is low by any measure, and certainly for a company that is posting renewed growth). But the analysts have remained hesitant. Half of them rate Syneron “Buy” while the other half rate it “Hold.” This is the mindset on Wall Street; it takes time for analysts to recover from their own errors. At the end of November, Doron Gerstel president of Syneron’s North American division, published an update on the company on Wall St.Net. According to Gerstel, things are back to where they were before, and if that is the case then Syneron is indeed one of the top stocks for 2007.

Published by Globes [online], Israel business news - www.globes.co.il - on December 12, 2006

[swampboots]

Buying the options as overdone!!!

[midastouch017]

Syneron Reports Q1 2006 Revenue Increase of 28.3% Over Q1 2005 to $23.7 Million

Tuesday May 9, 6:40 am ET

YOKNEAM, ISRAEL--(MARKET WIRE)--May 9, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announced financial results for the first quarter of fiscal year 2006 ended March 31, 2006.

Revenues for the first quarter of 2006 were $23.7 million, an increase of 28.3% from $18.5 million for the same period in 2005. Net income for the first quarter of 2006 on a US GAAP basis ("GAAP"), including stock-based compensation expense related to the Company's adoption of Financial Accounting Standards (FAS) No. 123R of approximately $1.5 million, was $8.8 million or $0.32 per diluted share, representing a net profit margin of 37.1%. In the first quarter of 2005, the company reported GAAP net income of $7.5 million or $0.27 per diluted share, representing a net profit margin of 40.5%. The gross profit margin for Q1 2006 was 85.3% compared to gross margins of 86.1% for Q1 2005. Excluding stock-based compensation expenses related, the gross profit margin for Q1 2006 was 85.6%.

On a normalized pro-forma basis, non-GAAP net income for the first quarter of 2006, excluding stock-based compensation expense, was $10.3 million, or $0.37 per diluted share, representing a net profit margin of 43.6% for Q1 2006. (Refer to the "Use of Non-GAAP Measures" section and accompanying financial table for reconciliation of GAAP financial information to Non-GAAP). The non-GAAP net income for the first quarter of 2005, excluding a one-time charge of $1.1 million was $8.6 million, or $0.32 per diluted share, representing a net profit margin of 46.6%.

Higher investment in sales and marketing and in R&D in the first quarter resulted in an increase of operating expenses. On a non-GAAP basis, R&D expenditure, as a percentage of revenue, rose to 6.7% from 5.4% in the first quarter of 2005. Sales and marketing expenditure, as a percentage of revenue, rose to 33.9% reflecting the growth of the sales force in North America and other parts of the world, marketing initiatives launched at major professional medical conferences and trade shows in the US and Europe, a major new training and education program and new marketing materials and tools.

Commenting on the results, Syneron CEO David Schlachet said, "We have increased our investments in sales and marketing and in R&D in the first quarter in accordance to the growth strategy for Syneron discussed at the start of the year. We plan to maintain the level of R&D expenditure at its current level of close to 7% of revenue given the strong R&D pipeline and our ambitious timeline for new product introduction. However, we expect sales and marketing expenditures to decrease as a percentage of sales as revenues rise over the next few quarters.

Syneron's financial position remains strong. On March 31, 2006, Syneron had a cash position (including long term deposits) of $138.3 million and Shareholders' equity of $156 million. At the end of March, trade receivables totaled $27.8 million. As of today, Syneron had collected $9.5 million of the outstanding receivables.

Conference call

Syneron Management will host a conference call to discuss the results at 8:30am ET today, May 9, 2006. Investors and other interested parties may access a live web cast through Syneron's web site at www.syneron.com. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site.

Use of Non-GAAP Measures

This press release provides financial measures for net income and basic and diluted earnings per share that exclude stock-based compensation expense and are therefore not calculated in accordance with generally accepted accounting principals (GAAP). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance that enhances management's and investors' ability to evaluate the Company's net income and earnings per share and to compare it with historical net income and earnings per share prior to the adoption of FAS 123R.

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when evaluating the business internally and therefore felt it important to make these non-GAAP adjustments available to investors.

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/060509/0127924.html

Dubi

[midastouch017]

FDA Clears Syneron's New Fast ST Applicator for Non-Invasive Treatment of Wrinkles

Thursday March 16, 9:21 am ET

Using New Applicator With Syneron's New eLight(TM) and eMax(TM) Platforms, Physicians Can Achieve Tightening of Skin via Wrinkle Reduction With the Fastest Treatment Time on the Market

YOKNEAM, ISRAEL and TORONTO--(MARKET WIRE)--Mar 16, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced that the US Food & Drug Administration (FDA) granted a 510(k) marketing clearance to Syneron's new ST applicator for non-invasive wrinkle treatment. Using the ST applicator, the ReFirme(TM) procedure offers a non-invasive, less painful alternative for patients wanting to achieve skin tightening and improvement in skin laxity through wrinkle reduction on the neck, face, and other areas of the body. With a pulse repetition rate of one pulse per second, and using Syneron's elôs(TM) technology, the ReFirme treatment with the ST applicator is by far the fastest and most effective on the market.

"A universal complaint among patients receiving traditional skin tightening treatments was the level of discomfort during the procedure," said Robert Sleightholm, MD, a plastic surgeon at Brampton Cosmetic Surgery and Laser Clinic in Brampton, Ontario. "Because of the lower level of energies needed to power ReFirme, patients are able to achieve the skin tightening and wrinkle improvement they desire without the risks or pain historically associated with treatments, even on the forehead or on a bony prominence. Patients I have treated using the ReFirme procedure also have smoother, plumper skin and see results more quickly than other skin tightening treatments I have used."

The new ST applicator works with both the new eLight(TM) and the eMax(TM) platforms from Syneron, powered by Syneron's unique elôs (electro-optical synergy) technology. Both platforms combine electrical energy (bi-polar radio frequency) and optical energy to enable highly efficient and safe treatments for patients.

The ST applicator expands further the broad range of functions of the recently launched eLight and eMax platforms. The eLight is Syneron's new complete elôs facial treatment system. In addition to now treating wrinkles using the ST applicator, the eLight can also further rejuvenate skin by treating a patient for vascular and pigmented lesions, and acne conditions with additional applicators. The eMax is the complete elôs workstation, covering all of the capabilities of the eLight as well as providing high-speed, laser-based hair removal and treatment for leg veins.

"With eLight, physicians will be able to treat vascular, pigmented, laxity and texture problems with one system. The new ST applicator, cleared by the FDA this week, will enable doctors to offer their patients a faster wrinkle reduction treatment with less discomfort than any other product on the market," said Dominic Serafino, Syneron's American President. "Our new eMax system will also incorporate the new ST applicator and will provide our customers with a complete face and body solution to improve any patient's appearance."

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) develops, manufactures and distributes medical aesthetic devices that are powered by elôs(TM), the combined-energy technology of bi-polar radio frequency and light. The Company's innovative elôs technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world including North American Headquarters in Canada, European Headquarters in Germany and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/060316/0113496.html

Dubi

[midastouch017]

Syneron's been spanked enough, says CIBC

07.3.06 | 15:29 By Shirley Yom-Tov

Last December, a moment before Syneron (TASE, Nasdaq: ELOS) warned the market that it would be missing fourth-quarter forecasts, CIBC downgraded the medical technology company.

The investment bank slashed its price target and anybody who heeded CIBC and sold the stock saved himself a 30% dive in share price from then to now.

Back in the present, CIBC feels that it's time to get back into Syneron, which makes lasers for cosmetic applications. The investment bank has upgraded its stock to Outperform and set a new 12-month price target, at $40. That is a hefty 48% above its closing price on Nasdaq last night.

Syneron held a conference with analysts at the American Association of Dermatology and the CIBC people came out of feeling upbeat about developments in the aesthetic therapies market, the bank explains.

One of Syneron's products is VelaSmooth, used to fight cellulite, and the analysts feel the company is well positioned to benefit from the upbeat trends in the sector.

In its presentation, the Syneron management predicted that the market for laser cosmetic treatments would continue to grow by 20% a year. The management said there are 300,000 people engaged in the field who could be potential clients for devices of the type the Israeli company sells.

At present Syneron is launching a new product, e-Line, which is supposed to tighten skin. Rival company Lumenis (Nasdaq:LUME.PK) sells a similar product to rejuvenate skin and remove unwanted hair. Syneron has an advantage in greater recognition of its brand name, the analysts suggest.

During 2006 Syneron is expected to seek regulatory approval to market a device for the noninvasive treatment of fat deposits. It is presently looking for a strategic marketing partner that sells directly to private consumers, to pitch a household skin rejuvenating product. CIBC believes it will be announcing an agreement this year.

The investment bank's $40 price target is 20 times estimated 2006 earnings per share or $2 per share, translating into profit of about $55 million. Syneron stock has been punished since the disappointment with its fourth-quarter results, CIBC writes. Time to stop the spanking.

http://www.haaretz.com/hasen/spages/691300.html

Dubi

[midastouch017]

Syneron Unveils New E-Systems for Aesthetic Applications at American Academy of Dermatology Meeting

Monday March 6, 10:22 am ET

YOKNEAM, ISRAEL and TORONTO--(MARKET WIRE)--Mar 6, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) this weekend debuted three new platforms to address medical aesthetic applications based on its elos(TM) (Electro-Optical Synergy) combined energy technology -- the first and only technology to combine Bi-Polar Radio Frequency (RF) and Light or Laser energies. The new eSystems make it easier than ever for physicians to address growing patient demands for no-down-time aesthetic procedures.

The new eLight platform uniquely combines Broad Spectrum Light with Bi-Polar Radio Frequency. The system provides a full facial solution for skin rejuvenation, including the treatment of superficial vascular and pigmented lesions, and acne applications. The system also includes a revolutionary new skin tightening modality, which is currently being sold outside the United States and is pending US Food & Drug Administration clearance.

The new eLaser platform combines Diode Laser technology with Bi-Polar Radio Frequency (RF) and offers ultrafast hair removal, as well as upgradeability to Syneron's proven leg vein and wrinkle reduction treatments.

Finally, the new eMax platform combines Bi-Polar Radio Frequency (RF) with multiple forms of light energy to deliver the complete range of Syneron's elos modalities in one multi-platform system.

Syneron's successful VelaSmooth(TM) system for the reduction of the appearance of cellulite is also being highlighted at the AAD. This system gained clearance from the US Food and Drug Administration last June and continues to grow in popularity both in the United States and in International markets.

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) develops, manufactures and distributes medical aesthetic devices that are powered by elos(TM), the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/060306/0112107.html

Dubi

[midastouch017]

Syneron misses analysts' estimates by two cents

The aesthetic medical device company's fourth quarter earnings per share still grew 46%, while revenue grew 36%.

Globes correspondent 13 Feb 06 17:40

Aesthetic medical device company Syneron Medical Ltd. (Nasdaq: ELOS) of Yokne'am has reported a net profit of $12 million for the fourth quarter of 2005, representing a 46% increase over the comparable quarter of 2004.
Fully diluted earnings per share were $0.43, up 43% on the corresponding quarter of 2004. Nevertheless, fourth quarter 2005 earnings per share were $0.02 below the consensus analysts' estimate.

Revenue rose 36% from $17.5 million for the fourth quarter of 2004 to $23.7 million for the fourth quarter of 2005, but it too was below the analysts' estimate, which was for revenue of $24.2 million.

The company's gross profit margin for the fourth quarter of 2005 87%, the same as in the fourth quarter of 2004.

Revenue for 2005 as a whole rose 51% to $87.4 million $57.9 million in 2004. The annual net profit on a US GAAP basis was $41.1 million, compared with $27.3 million in 2004.

Earnings per diluted share on a US GAAP basis were $1.48. The US GAAP-based income includes $3.5 million of expenses for the company's secondary offering in March 2005 and the Thermage settlement in June 2005.

On a normalized proforma basis, net income was $44.6 million and EPS per diluted share $1.61, compared with $1.14 per diluted share for 2004.

R&D costs rose from $3.1 million in 2004 to $5 million in 2005.

During 2005, Syneron generated cash of $31.3 million from operations and $11.7 million from the exercise of options, giving a total cash position at the end of 2005 of $134.1 million, and shareholders' equity of $145.2 million.

Syneron CEO David Schlachet said, "We are very pleased with our ability to execute our unique business model and with our extremely high profitability. Although we have seen a slow down in our rate of growth in the fourth quarter, we are confident in our ability to continue Syneron's growth in 2006 and beyond, while maintaining our unique profitability structure." Mr. Schlachet continued, "In its first five years, Syneron has demonstrated its ability to grow at a very high rate taking advantage of its proprietary elos™ technology. With 51% growth in revenues in 2005, we estimate that our global market share has risen to approximately 15% with an installed world wide base of more than 4,000 units." Remarking on Syneron's future plans, Mr. Schlachet continued, "Now that Syneron has become a more mature company our strategic objective is to strengthen our position as a market leader by building the long-term plans of the company and the infrastructure to support it. Syneron is investing in enhancing its distribution channels and in the marketing and promotion of its products and technology."

Syneron said that, because of seasonality in the sector, it would issue annual revenue guidance rather than quarterly guidance. For 2006, Syneron sees revenue of $113-120 million, a 29-37% increase over 2005 revenue, and gross margin maintained at 85 to 87%. For the first quarter of 2006, the company expects about the same revenue as for the fourth quarter of 2005.

Published by Globes [online], Israel business news - www.globes.co.il - on February 13, 2006

Dubi

[midastouch017]

Syneron is trading at 31% discount to peers, says Unterberg

12.2.06 | 13:49 By Sharon Shpurer

Syneron (TASE, Nasdaq: ELOS) is trading at a discount of 31% compared with its peer group, says the investment bank CE Unterberg Towbin.

Its peer group, by the way, is small medical technology companies, mainly ones making products for laser and cosmetic therapies.

Tomorrow Syneron will be publishing its fourth-quarter and 2005 financial statements.

Unterberg predicts 38% quarterly revenue growth against the parallel quarter to $24.2 million, and a 51% leap in profit to 45 cents per share.

The company guided investors to expect $24 million sales. In January 2006, it lowered its guidance downward from $27.3 million - $28.3 million, which helped it lose 40% of its market cap since mid-December.

The company's market cap had been more than a billion dollars but has sunk to $685 million.

At the time Syneron tried to soften the blow, reporting that its fourth-quarter results will not be including transactions worth between $3 million to $4 million. The devices had been shipped and if these transactions were included, its sales would have been $27 million, as expected.

The company has not yet provided guidance for 2006. Wall Street expects earnings in the range of $1.85 to $2.42 per share on revenues of $106.8 million to $127 million.

http://www.haaretz.com/hasen/spages/681820.html

Dubi

[midastouch017]

Syneron Announces CFO Appointment

Thursday February 9, 4:19 pm ET

YOKNEAM, ISRAEL--(MARKET WIRE)--Feb 9, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, today announced the appointment of David Seligman as its Chief Financial Officer.

Prior to joining Syneron, Mr. Seligman, 47, was Chief Financial Officer for several public companies traded on NASDAQ. Mr. Seligman served as CFO of RADVISION, where he took part in its very successful initial public offering, and as CFO of LanOptics. In his most recent position, Mr. Seligman served as CFO of NUR Macroprinters where he took part in designing and implementing the financial initiatives which contributed to the company's turnaround. Mr. Seligman has also held several other financial positions in hi-tech companies in the US and Israel. Mr. Seligman has a B.A. in Political Science and Geography and an M.B.A. in Accounting and Finance from Tel Aviv University.

David Schlachet commented: "David's highly respected credibility within the financial community and his strong business background makes him well-suited to become part of Syneron's senior management. We look forward to the contributions he will make as he joins Syneron and leads our financial team worldwide."

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) develops, manufactures and distributes medical aesthetic devices that are powered by elos™, the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/060209/0109235.html

Dubi

[midastouch017]

Syneron’s Shimon Eckhouse Israeli entrepreneur of the year

Eckhouse will represent Israel in Ernst & Young’s international entrepreneur of the year competition.

(#msg-9326200)

Dubi

[midastouch017]

Syneron Establishes Two Strategic Sales Alliances in Canada

1/9/2006 7:00:05 AM

YOKNEAM, ISRAEL, Jan 09, 2006 (MARKET WIRE via COMTEX) -- Syneron Medical Ltd. (ELOS) today announced the formation of strategic alliances in Canada with two of the country's leading medical equipment and supply distributors. The two agreements give Syneron across-the-board direct access to the broad market of both English-speaking and French-speaking physicians in Canada.

In the first agreement, Syneron has established a strategic partnership with Medical Mart Supplies Ltd., a privately owned Canadian wholesale distributor, with 30 years' experience as a provider of full-service supply chain solutions to the health care industry. Medical Mart employees 33 direct sales reps across Canada with access to 35,000, primarily English-speaking physicians.

In the second agreement, Syneron is establishing a strategic partnership with Dufort & Lavigne Ltee, a privately owned Canadian distribution company providing medical supplies and equipment to the physician community in Quebec for over 40 years. Dufort & Lavigne employees 10 direct sales reps with access to 7,800 physicians within the province of Quebec.

Under the terms of the alliance, both Medical Mart and Dufort & Lavigne will work with Syneron to develop the market for Syneron's full platform of elos(TM)-based aesthetic medical devices among physicians in Canada. Syneron will work in tandem as a medical specialist resource to educate physicians, particularly outside the traditional market of plastic surgeons and dermatologists, on our exclusive elos(TM) technologies and the many value-added programs available to ensure practice management success.

Dominic Serafino, President of Syneron North America, commented that "There is a very significant opportunity to market our unique Syneron equipment to physicians in Canada who like their American counterparts are looking to augment the revenue base in their medical practice. In the US, 60-70% of our sales are to physicians outside the traditional market of dermatologists and plastic surgeons, whereas in Canada this sector of the market has not being accessed to nearly the same degree. We have chosen our strategic partners Medical Mart Supplies Ltd. and Dufort & Lavigne Ltee because they share our belief in the great unexploited potential to sell our aesthetic medical equipment into their large client base."

About Syneron

Syneron Medical Ltd. (ELOS) develops, manufactures and distributes medical aesthetic devices that are powered by elos(TM), the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

For more information, please contact Judith Kleinman, VP Investor Relations, tel: [phone], email: [e-mail].

Syneron, the Syneron logo and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. Elos (Electro-Optical Synergy) is a proprietary technology of Syneron Medical. All other names are the property of their respective owners.

Dubi

[midastouch017]

"You have to cope"

Syneron's Shimon Eckhouse on finding himself on the wrong side of sales guidance.

Tali Tsipori 3 Jan 06 18:55

The announcement released by aesthetic medicine device company Syneron Medical Ltd. (Nasdaq: ELOS) at 7 am EST this morning, as US investors woke for the resumption of work after the New Year holiday, probably did not make them fall out of bed. The sharp fall in the company's stock price in the two last trading sessions of 2005, and the dark warnings of investment house CIBC, presaged just such an announcement.
Syneron, whose products are mainly for various kinds of skin treatments, now expects to report revenue of $24 million for the fourth quarter of 2005, compared with previous guidance of $27.3-28.3 million. In its announcement, the company said that orders worth $3-4 million that had been invoiced and shipped would not be recognized as revenue because they could not be delivered over the holiday period.

"We have a very strict revenue recognition policy," says Syneron founder and chairman Shimon Eckhouse. "Until the customer receives the product, we don’t recognize any revenue from him. The end of the fourth quarter is always a busy time. In 2005, December 31 fell on a Saturday, and January 1 on a Sunday, which limited our ability to supply orders to some of our customers."

It may be that some of the company's problems in the fourth quarter were due to the holidays, but it should be noted that even had Syneron posted revenue of $27-28 million, it would still have only met its guidance, and would not have beaten the analysts' estimates. "True, from the investors' point of view, we disappointed them, as it were, but this is an unending game that's impossible to win," says Eckhouse. "If we had been too aggressive, and then not met our guidance, the share would have fallen. If we are conservative, as we take care to be, the share will still fall, as in fact happened. These are unpleasant situations with which we have to cope."

Syneron expects to report revenue of some $88 million for 2005 as a whole, 50% more than in 2004. Perhaps to sugar the pill, Syneron chose to open today's announcement with this growth rate, rather than with the fourth quarter results. The analysts' consensus estimate, before today's warning, was for annual revenue of $92 million, at the upper limit of the company's $91-92 million guidance. The consensus estimate for fourth quarter revenue was $28.7 million. For earnings per share, the consensus estimate was for $0.54 in the fourth quarter, and $1.17 for the year.

Globes: Do you have a projection for this year's growth rate?

Eckhouse: "No, still not. We are only in the first few days of the year, and, as always, we want to be cautious about making projections. We therefore prefer not to make announcements at this time."

About 2006, Eckhouse adds that Syneron is in the process of expanding its sales force, which in the short term will mean higher sales and administration expenses, but which, according to Eckhouse, "will have positive significance" in the long term.

Will the level of profitability you have accustomed investors to seeing be maintained in the fourth quarter?

"As far as gross profit is concerned, I can say that it will. It's hard for me to answer about net profit at the moment."

I suppose the past few days haven't been easy.

"Yes, but that's part of the job in a public company. It's not pleasant, but you have to deal with situations like this one as well. We are very happy with what's happening at the company, and hope for continued growth."

Published by Globes [online], Israel business news - www.globes.co.il - on January 3, 2006

Dubi

[midastouch017]

I sense a large probability that Syneron Medical Ltd. (Nasdaq: ELOS) will issue a profit warning. Friday’s 11% plunge in the share was due to a downgraded recommendation from CIBC, which fears that the company will miss its sales target. In a "Globes" interview on Sunday, acting Syneron Medical chairman Dr. Shimon Eckhouse declined to comment on the quarter, claiming that the figures had not yet been collected. This claim seems odd to me in the computer era, and constitutes at least an indication that the quarter is borderline, with the company scrambling to get its distributors to up their sales figures. In addition, a sentence like, “I’m here to build value for investors in the long term,” usually hints at a problem in the short term.

Synernon’s share began its slide from a peak of $46 on December 13, accompanied by a large trading volume. At the time, the fall in the share was attributed to a downgraded recommendation by CNBC guru James Cramer, who told investors to take some of their large profits in the share off the table, because, as he puts it: "Bulls make money. Bears make money. Pigs get slaughtered." The share indeed shed 32% of its peak value, but I suspect that, even then, the fall was due to problems with the company’s quarterly results, not just what Cramer said.

Cramer also recommended switching to the share of a competitor just after its IPO, and similar recommendations of his for other shares did not cause such a sharp response. After all, he didn’t say anything bad about Syneron for either the short or long term; he only repeated his investment philosophy, which advocates taking some of the profits gained from a rising share.

http://www.globes.co.il/serveen//globes/docView.asp?did=1000046255&fid=1176

Dubi

[midastouch017]

Syneron Announces Preliminary Results for 2005

Tuesday January 3, 7:00 am ET

Preliminary Results Show Revenue Increased More Than 50% in 2005

YOKNEAM, ISRAEL--(MARKET WIRE)--Jan 3, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced that for the year ended December 31, 2005, preliminary results indicate revenues of approximately $88 million, a greater than 50% increase from 2004. This recognized revenue does not include $3-4 million that were invoiced and shipped, but not delivered due to logistical holiday limitations preventing the delivery and/or acceptance of deliveries during the abbreviated holiday week at the end of the last quarter.

For Q4 2005, while preliminary results showed recognized revenue of approximately $24 million, invoicing and shipments totaled over $27 million.

Commenting on the results, Syneron CEO David Schlachet said, "Since assuming the role of CEO in the second half of the fourth quarter, I have worked intensely with our sales teams worldwide to meet our sales targets. We have reorganized the structure of the North American sales force in a direction that we believe will increase further the efficiency of the organization over the long term. Our organization now consists of 45 salespeople in North America, organized in seven territories each with a dedicated regional manager. Previously, our North American sales team was grouped into only four territories which had become too cumbersome for each regional manager to lead effectively."

Conference call

Syneron Management will host a conference call to discuss the preliminary results 9:00am ET today, January 3, 2006. Investors and other interested parties may access a live webcast through Syneron's web site at www.syneron.com. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site.

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) develops, manufactures and distributes medical aesthetic devices that are powered by elos(TM), the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/060103/0105076.html

Israel's Syneron says 2005 revenue rose 50 pct
Tue Jan 3, 2006 07:13 AM ET
Jan 3 (Reuters) - Syneron Medical Ltd. (ELOS.O: Quote, Profile, Research) on Tuesday said according to its preliminary results, revenue for 2005 rose more than 50 percent from the previous year.
The Israeli company, in a news release said it expects revenue of about $88 million for 2005, excluding $3 million to $4 million that were invoiced and shipped, but not delivered.

For the fourth quarter, Syneron's recognized revenue was about $24 million, while invoicing and shipments totaled over $27 million, it said. (Reporting by Tuhin Kar in Bangalore)

http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh11828_2006-01-03_12-13-18_wna...

Dubi

[midastouch017]

Syneron diving 9% after CIBC downgrade to Sector Perform

30.12.05 | 17:44 By Omri Cohen
CIBC World Markets had been bullish on Syneron (TASE, Nasdaq: ELOS) stock, but the investment bank downgraded it today from Outperform to Sector Perform.
The downgrade sent Syneron stock reeling. As of writing it was down 9.3% to $32.40.
CIBC pointed to new competition in devices for cosmetic treatments and concerns that Syneron would have difficulty meeting expectations for the last quarter of 2005.
In parallel the analysts lowered their forecasts for Syneron this year and next.
Syneron stock has lost 30% in the space of two weeks, from its record height of $46.
For the fourth quarter CIBC now expects $26.3 million sales instead of $31.5 million, and lowered its earnings estimate to 50 cents per share, from 58 cents.
In October-December the average analyst forecast had been $29 million revenues and 54 cents per share in earnings.
It also lowered the figures for 2006 to sales of $116 million, from $137 million, or growth of 29% against $90 million sales this year. That figure for 2005 represents 55% growth against 2004.

CIBC also cut its earnings forecast to $2.04 per share instead of $2.39.

It does note that the launch of VelaSmooth, a cellulite treatment, has been successful and sales continued to grow in the fourth quarter. Growth drivers include Syneron's dental product line, and a noninvasive fat treatment device slated for launch in 2007.

http://www.haaretz.com/hasen/spages/664456.html

Dubi

[midastouch017]

Syneron Announces Resignation of Moshe Mizrahy From Board of Directors
Monday December 19, 7:30 am ET


YOKNEAM, ISRAEL--(MARKET WIRE)--Dec 19, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced the resignation of former CEO, Moshe Mizrahy, from the Board of Directors of Syneron Medical Ltd. No replacement has yet been appointed.
Shimon Eckhouse, Chairman of the Board of Syneron, commented: "Moshe made an enormous contribution to the development and growth of Syneron from its start-up phase to the medical aesthetics leader that we are today. With our new management team, we are well positioned to take the company to the next phase of its growth. In the name of Syneron's shareholders, customers and employees, I want to thank Moshe for his hard work and contribution to Syneron."

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos(TM) combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

Syneron, the Syneron logo, and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. Elos (Electro-Optical Synergy) is a proprietary technology of Syneron Medical. All other names are the property of their respective owners.



Contact:
For more information, please contact:
Judith Kleinman
VP Investor Relations
Syneron Medical Ltd.
[phone]
email: Email Contact.


Source: Syneron Medical

http://biz.yahoo.com/iw/051219/0104380.html

Dubi

[midastouch017]

Jim Cramer said to take profit and Syneron sank 9.4%
14.12.05 | 13:58 By Omri Cohen

If you want a stock to soar, pray that Wall Street guru Jim Cramer likes it. The CNBC star hosts a daily show, Mad Money, in which he recommends some stocks and roasts others. He has a faithful following of day traders and investors awaiting the word, and last night the Israeli company Syneron (TASE, Nasdaq: ELOS) was not on his like list.
Syneron stock sank 9.4% on five times its three-month average turnover after Cramer spoke, recommending that investors take profit from his former fave.

Less than a month ago, Cramer praised the company, which makes laser and light devices for cosmetic treatments. Asked by a viewer about its rival LaserScope, Cramer snorted something along the lines of how the guy could come on air asking about a dog like that when he had Syneron to offer.

The next day Cramer recommended Syneron again, calling it the best play in lasers.

Syneron last year

It took a few days but Syneron started to soar. As Tuesday began, its stock had risen 22% in the space of two weeks to a new high of $46, but after the day ended, the romance with Jim was over. Cramer counseled investors to cash in their gains and ride the next "newest, hottest laser company", Cynosure (Nasdaq:CYNO), which just floated on Nasdaq last week and began trading on Friday.

Cramer may not be able to move mountains, but he evidently can impact share prices. Syneron tumbled 9.4% and Cynosure soared 13%.

Citigroup doesn't buy Cramer's line. It said investors had overreacted and that today brings a buy opportunity for Syneron stock. In early November, Citi had granted a Buy rating for Syneron.

http://www.haaretz.com/hasen/spages/657932.html

Dubi

[midastouch017]

Recent Study Provides Further Support for the Efficacy of Polaris(TM) WR in Wrinkle Reduction
Monday December 12, 9:00 am ET


Dermatologic Surgery Journal Reports on Positive Findings of a Six-Month Study of elos(TM) Technology Used to Treat Wrinkles

YOKNEAM, ISRAEL and TORONTO--(MARKET WIRE)--Dec 12, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced that the results of a two-center study found Syneron's Polaris™ WR effectively decreases the appearance of wrinkles and improves skin texture. In the article to be published this week in the Dermatologic Surgery Journal (2005:31), Dr. Neil S. Sadick of the Weill Medical College of Cornell University, who is on the research board for Syneron, and Dr. Mario A. Trelles* of the Instituto Medico Vilafortuny in Spain, conducted a study of 23 adult patients (20 female and 3 male) aged 38 to 68, classified with grade II to IV wrinkling. At the conclusion of the treatment period, all of the patients recorded a clear improvement in skin smoothness and texture, and an improvement in the appearance of wrinkles.

The Polaris WR, powered by the unique elos™ (electro-optical synergy) technology, combines 900nm diode laser energy simultaneously with bipolar RF current. The synergetic combination of these two energies enables the system to use less optical energy density resulting in a safer and more effective technology for the treatment of wrinkles than other light or laser-based systems.

"The positive results witnessed by our study patients are proof that the unique combination of RF and diode laser technology significantly decreases the appearance of wrinkles," said Neil S. Sadick, M.D., department of dermatology, Weill Medical College of Cornell University, and founding director, Sadick Aesthetic Surgery & Dermatology in New York. "The histology assessment from the punch biopsies conducted on four patients showed an overall improvement throughout the skin by increasing epidermal thickness and creating more compact collagen fibers."

A similar peer-reviewed study published in the same journal earlier this year was cited within this clinical paper whereby Drs. Alster and Doshi also observed measurable improvement in both facial wrinkles and skin laxity with the Polaris WR.

"We are delighted to see such positive results and high patient satisfaction in yet another clinical study," said Domenic Serafino, president of Syneron North America. "The Polaris WR has proven to be a strong market leader, and the results published in this study further confirm its long-term effectiveness. We truly believe that the unique combination of technologies found in the Polaris WR and all our elos systems brings a very appealing treatment option for physicians and patients alike."

For media interested in the full text, please contact [e-mail].

For investors interested in the full text, please contact [e-mail].

http://biz.yahoo.com/iw/051212/0103670.html

Dubi

[midastouch017]

Moshe Mizrahi sells remaining Syneron stake for $50m

Mizrahi, a former CEO at Syneron, has earned $80 million from selling the company’s shares.

Tali Tsipori 28 Nov 05 14:27

Yokne’am-based Syneron Medical Ltd. (Nasdaq: ELOS), founded only four years ago, held its IPO less than eighteen months ago. Syneron develops cosmetic equipment.
Moshe Mizrahi was CEO of Syneron until three weeks ago. He has accompanied the company for the past four years, leading it to one of the most impressive exits achieved by an Israeli manager. Two weeks after resigning his position, Mizrahi decided to start selling his holding in the company.

Three separate reports to the US Securities and Exchange Commission (SEC) show that Mizrahi sold his remaining 4.9% of the company, 1.22 million shares, for $50 million. Mizrahi’s sell-off is perfectly timed - Syneron’s shares has now reached a peak of $40, reflecting a $1 billion market cap, more than triple its value for its IPO.

Last March, as part of Syneron’s offer for sale, Mizrahi sold shares for $23.3 million. His total gross proceeds from selling Syneron shares are therefore currently $80 million (NIS 370 million). Within a year, Mizrahi has become one of the wealthiest people in Israel.

Mizrahi is still a director in Syneron, a position requiring less exposure to investors. One of the few times he was exposed to the public was at a conference organized by the Israel Venture Capital (IVC) Research Center for Israeli high-tech companies on the subject of global capital markets, a few days after Syneron’s secondary issue. The title of Mizrahi’s lecture at the conference was, “Lessons learned from an IPO from the company’s perspective.”

In his lecture, Mizrahi recommended that parties at interest not sell shares in the context of IPOs. “Don’t try to sell shares in an IPO, because you’ll have to answer questions during the road show from people asking why managers are selling shares. Experience shows that answering questions of this type wastes valuable time. If you want to sell shares, wait six months,” he said. Syneron waited patiently for six months after its IPO, then, after the share surged, made one of the biggest offers for sale ever by an Israeli company on Nasdaq.

Published by Globes [online] - www.globes.co.il - on November 28, 2005

Dubi

[midastouch017]

Thu: We need more Yokne’ams
Given Imaging and Syneron Medical share an honorable mention from Zacks, and a town that should be a model for Israeli tech investment.
Shlomo Greenberg

Zacks analyst Charles Rotblut CPA periodically compares the circumstances of different industries in the US. This week, he looked at alternatives to the housing industry, which he said “received an unwelcome jolt”. In his opinion, what happened to the prestigious company Toll Brother (NYSE:TOL), which disappointed investors by missing fiscal fourth quarter earnings and cutting its guidance for fiscal year 2006 two weeks ago - signs of cracks in the strong US housing industry, and implying that money should move to other sectors.
But where? Rotblat suggests that medical instruments is the answer for money seeking long-term growth investments. I wholeheartedly agree. “product innovation and strong profit reports are fueling bullish sentiment within this group.” And who does Rotblat cite as examples? Boston Scientific (NYSE:BSX)? No. Johnson and Johnson (NYSE:JNJ). No again. He mentions Syneron Medical Ltd. (Nasdaq:ELOS) and Given Imaging Ltd. (Nasdaq: GIVN; TASE:GIVN).

I, as you know, believe that medicine and healthcare in general are the best investments in town, regardless of when. Pharmaceuticals and medical equipment are two kinds of products that have no 1,000:1 chance of being in oversupply. Both Syneron and Given Imaging, as well as several other very successful companies, are based in Yokne’am.

I mention Yokne’am because it has become a very important technology center, with a strong reputation outside of Israel, too. In my opinion, the government should pour money into places like it, in order to create two things. One is a good and worthwhile environment for investors and entrepreneurs, so they’ll invest in Yokne’am, rather than in Palo Alto or in the Netherlands. Second, such investments make a quick return and boost local employment.

I don’t know if you know, but Israel has no high-tech advantage today except for its people. Therefore, to those seeking how to leave, I recommend to the government to set up and foster more Yokne’ams throughout the country. Not only are they environmentally pleasing, they give reasons for visitors to investment.

http://www.globes.co.il/serveEN/globes/nodeView.asp?fid=1052

Dubi

[bluebear]

Chart looks very good tonight. If it starts upward tomorrow, I'm in.

[midastouch017]

Syneron promotes CFO as chief executive
Thu Nov 3, 2005 08:36 AM ET

Nov 3 (Reuters) - Syneron Medical Ltd. (ELOS.O: Quote, Profile, Research) on Thursday said it appointed its Chief Financial Officer David Schlachet as chief executive officer, replacing Moshe Mizrahy.
A company spokesperson said Mizrahy, who has been associated with the company since its inception in 2000, resigned, but did not give any reason.

However, Mizrahy will stay on Syneron board for a short period, the spokesperson said.

In a news release, the company also said it appointed Shimon Eckhouse as active chairman. (Reporting by Sunil Mathew Paul in Bangalore and Steven Scheer in Jerusalem)

http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh94357_2005-11-03_13-36-12_bng...

Dubi

[midastouch017]

Syneron Medical Reports Record 2005 Third Quarter Results, Increased Guidance and Management Changes

Thursday November 3, 6:22 am ET

68% Increase in Revenue and Doubling of Net Income Confirms Syneron Strengthening Competitive Advantage in the Medical Aesthetic Sector


YOKNEAM, ISRAEL--(MARKET WIRE)--Nov 3, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today reported results for the third quarter and first nine months of 2005, as well as management changes for the next phase of its corporate growth strategy.

Revenue for the third quarter of 2005 rose 68% to $25 million, compared to $14.9 million reported in the third quarter of 2004. The VelaSmooth(TM) played a significant role in the growth of North American sales. Also contributing to the strong rise in sales was the active promotion of bundled sales in the U.S. during the third quarter of 2005, which contributed to a 40-50% increase in the average transaction size. North America accounted for 66% of total sales from July to September.

Operating expenses rose 27.6% during the third quarter of 2005 to $8.3 million, compared to $6.5 million a year ago. The limited rise in operating expenses reflects the leveraged effect of the sharp rise in sales, given the efficiencies of Syneron's cost structure, as well as lower marketing and sales costs in the third quarter of 2005.

Third quarter operating income doubled to $13.6 million, from $6.7 million in the third quarter of 2004. Operating margins rose to 54% in the third quarter, compared to 45% in the third quarter last year. Third quarter 2005 net income rose to $14.6 million, compared to $7.3 million net income reported in Q3 2004. The net income margin rose from 49% in Q3 2004 to 58% in Q3 2005. Earnings per diluted share were $0.53 in Q3 2005, compared with $0.29 in Q3 2004.

Revenue for the nine months to September 30, 2005 rose 57.6% to $63.7 million, compared to $40.4 million reported in the first nine months of 2004. Operating expenses for the first nine months of 2005 on a pro forma basis (excluding expenses for the secondary offering and the Thermage settlement) were $24.5 million, compared to $17.5 million recorded in the same period in 2004. Nine-month operating income grew 68.2% on a pro forma basis to $30.8 million, from $18.3 million in the first nine months of 2004. Nine-month net income was $32.5 million pro forma, compared to the $19.1 million net income reported in the same period the previous year. On a US GAAP basis, including the costs of the Thermage settlement and secondary offering, operating expenses for the first nine months of 2005 were $28 million, operating income for the nine months was $27.3 million, with net income of $29 million. Earnings per diluted share, on a pro forma basis for the first nine months of 2005, were $1.18, while on a GAAP basis, earnings per diluted share were $1.05.

Commenting on the results, Moshe Mizrahy, CEO, said, "The results for the third quarter clearly reflect the success of our efforts to create the most competitive and diversified product portfolio for use by medical aesthetic professionals. At the most basic level, our success derives from the competitive advantage of the elos technology which enables us to produce the safest, most effective equipment in the industry, as discussed in some 40 peer-reviewed articles, with maximum manufacturing efficiencies. At a higher level, our success also reflects the achievements of individuals and groups within Syneron, such as the sales and marketing management which developed and implemented marketing strategies that capitalize on the competitive advantages of Syneron's broad product portfolio."

Syneron is raising revenue guidance for 2005 to $91-92 million from $84-85 million.

Syneron's financial position remains strong. In the third quarter, Syneron generated cash of $13.5 million from operations and $2.6 million from exercise of options and interest, for a total cash position on September 30, 2005 of $118.5 million, with no debt. Shareholders' equity was $125.7 million at the end of the third quarter.

Management Changes

Looking forward to the next phase of its strategic corporate development, Syneron is today announcing changes in its senior management. The changes include the transition of responsibility as Chief Executive from Moshe Mizrahy, who has been instrumental in the rapid growth of Syneron since its inception and for Syneron's highly successful first year as a public company, to David Schlachet, currently CFO of Syneron, and the appointment of Shimon Eckhouse as active chairman.

Commenting on the management transition, Shimon Eckhouse said, "Moshe Mizrahy's skills with managing early-stage companies and developing Syneron's markets have been instrumental in achieving worldwide market recognition of the competitive advantages of our elos(TM) technology and Syneron's wide portfolio of medical aesthetic platforms. Looking to the next phase of Syneron's strategic development, David Schlachet brings broad senior managerial experience and extensive experience in implementing M&A strategies, having served as the chairman and CEO of several large publicly traded companies, as well as specific experience in the medical technology sector having been a managing partner of an Israeli venture fund specializing in medical devices and biotechnology and as Vice President of the Weizmann Institute of Science in Israel."

http://biz.yahoo.com/iw/051103/0100090.html

Dubi

[midastouch017]

Syneron Medical to Announce Third Quarter Financial Results on November 3, 2005
Monday October 10, 8:00 am ET


YOKNEAM, ISRAEL--(MARKET WIRE)--Oct 10, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announced that it will release its third quarter financial results for the period ending September 30, 2005 on Thursday, November 3, 2005, before market opening. The earnings release will be available on Syneron's web site at www.syneron.com.
Syneron management will host a conference call and live webcast at 10:00am (ET) on the same day. A question & answer session will follow management discussion of events in the third quarter.

Investors and other interested parties may access a live webcast through Syneron's web site at www.syneron.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site.

http://biz.yahoo.com/iw/051010/097393.html

Dubi

[midastouch017]

Syneron loses exclusivity: American Laser Centers to buy from Lumenis too
29.9.2005 | 11:32
Shirley Yom Tov

Lumenis (Nasdaq:LUME.PK) last night published a highly significant announcement on its website: it has entered an agreement with American Laser Centers, a chain of cosmetic treatment clinics.

Lumenis explained in the announcement, which it had not yet released to the general media last night, that the agreement is for two years.

It did not disclose any financials but the relationship is probably worth a few million dollars.

The more interesting aspect of the announcement is that until now, American Laser Centers had bought its laser gear exclusively from Lumenis' bitter arch-rival, Syneron (TASE, Nasdaq:ELOS). Now both Israeli companies will be supplying gear side by side.

Just two weeks ago Syneron announced a $6 million deal to sell equipment to American Laser Centers.

Syneron had said that American Laser Centers would be buying 100 systems including the VelaSmooth anti-cellulite device, and the Aurora depilator. It added that the systems would be supplied within half a year.

Lumenis had done business wit Advanced Laser Centers, which American Laser Centers recently acquired. There had been speculation that the merger would elbow out Lumenis: but the result seems to have been quite the opposite.

http://tinyurl.com/dgl8k

Dubi

[midastouch017]

Syneron beats the odds
CIBC chose Syneron Medical as one of nine recommended small companies. The Israeli company has succeeded well in the highly competitive cosmetics field.
Shlomo Greenberg

In 1975, CIBC began a tradition of locating companies that were worthwhile investments. 1,098 companies have been included in this group since then, and 601 of them have risen, while 445 have fallen. The group for 2005 included 52 companies, five of which were Israeli. In addition to all the economic criteria that CIBC checked for every company, CIBC chooses its investment portfolio according to pre-selected categories. Like the S&P 500 index, 68% of these portfolio companies are in the large company category, while 32% are small and medium-sized. Small companies are defined as those with a market cap below $1.5 billion, a group that includes Israeli companies M-Systems Flash Disk Pioneers (Nasdaq: FLSH), with a $1.1 billion market cap, and Syneron Medical Ltd. (Nasdaq: ELOS), with a $900 million market cap. These two “small” Israeli shares are among the nine “small companies” in CIBC’s portfolio.
Israeli companies Comverse Technology (Nasdaq: CMVT), with a $5.1 billion market cap, and Amdocs (NYSE: DOX), with a $5.2 billion market cap, are among the sixteen portfolio companies classed as medium-sized. Only one Israeli company, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), is among the 27 large companies in the portfolio, which includes giants like General Electric (NYSE: GE), Wal-Mart Stores (NYSE: WMT), and Johnson and Johnson (NYSE: JNJ).

CIBC analysts explain the logic behind each one of the companies chosen for their focus group. Take Syneron Medical, for example, whose share was at $37 when the group was chosen. The share has since fallen slightly to $36, but that makes no difference; the recommended portfolio is for eighteen months ahead.

What makes Syneron Medical so interesting? After all, the share was one of the best investments over the past year, maybe even a leader. The price is not cheap, and competition in the company’s sector looks very extremely intense. It’s therefore important to understand what led CIBC to add this share to its portfolio and recommend buying it now.

To begin with, Syneron Medical’s products generate a quick return on investment, which is vitally important for doctors and clinics making decisions about investments in cosmetics. CIBC’s experts emphasize the company’s advantage in competition. Not only does Syneron have no fear of its competition, but the company also has a promising pipeline of products being developed, which will enable it to maintain control in its niche. The main risk in Syneron Medical cited by CIBC is what is referred to as the “Israeli risk”. Syneron Medical’s capabilities led CIBC to give a target price of $52 for the share, 44% higher than its current market price.

I get the impression that what impressed CIBC’s analyst is the capability demonstrated by Syneron Medical since its founding, and, course, the ability of its management. What the analyst is really telling us is that here is a company that has made a new start, against all the odds, and made a great success out of it. What Syneron Medical chairman Dr. Shimon Eckhouse has done shows outstanding ability on his part and that of his team. Those who know Main Street, especially competitive industries like cosmetics, know how hard it is to get a new company into a fiercely competitive field, especially when the entrepreneurs know that their competitors will do everything to prevent them from succeeding. If Syneron has succeeded so much in spite of that, it means that the company has products, pricing ability, and, most importantly, excellent management.

Published by Globes [online] - www.globes.co.il - on September 27, 2005

http://www.globes.co.il/serveEN/globes/nodeView.asp?fid=1052

Dubi

[midastouch017]

Syneron to Present at the UBS Global Life Sciences Conference
Thursday September 22, 8:00 am ET


YOKNEAM, ISRAEL--(MARKET WIRE)--Sep 22, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, announced today that Shimon Eckhouse, the Company's Chairman, will participate in the UBS Global Life Sciences Conference on Thursday, September 29, 2005 in New York City. Syneron is scheduled to present at 9:30 a.m. E.T.
The presentation will be broadcast live over the Internet and can be accessed through the investor section on the Syneron's Web site at www.syneron.com or directly on http://event.streamx.us/event/20050926. Please go to the Web site a few minutes early, as it may be necessary to download audio software to hear the presentation. An archived replay of the presentation will also be available approximately one hour following the live presentation.

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) manufactures and distributes medical aesthetic devices that are powered by elos, the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/050922/095927.html

Dubi

[midastouch017]

Syneron wins $6m order from American Laser Centers

American Laser Centers will expand its activity to include cellulite treatment with Syneron's VelaSmooth product.

Globes correspondent 18 Sep 05 11:24

On Friday, Syneron Medical Ltd. (Nasdaq: ELOS) and Syneron North America (NasdaqNM:ELOS - News) announced that American Laser Centers (ALC) would buy $6 million worth of Syneron equipment for its centers throughout the US.
ALC evaluated Syneron's VelaSmooth, and decided to expand the activity of its clinics from hair removal and skin rejuvenation to include cellulite treatment. ALC will purchase 100 Syneron platforms with delivery scheduled over the next six months. The order includes both VelaSmooth and the Aurora hair removal and FotoFacial treatments system.

ALC has more than 100 physician-supervised locations in the US.

Syneron North America president Domenic Serafino said, "By working even more closely with a medical chain like ALC, Syneron will achieve greater market awareness for the elos technology and Syneron's wide portfolio of medical aesthetic platforms."

Published by Globes [online], Israel business news - www.globes.co.il - on September 18, 2005


Dubi

[midastouch017]

Syneron Announces $6.0M Equipment Sale to American Laser Centers
Friday September 16, 8:00 am ET
Syneron Expands Relationship With Nation's Largest Physician-Supervised Aesthetic Medical Clinic Chain


YOKNEAM, ISRAEL and TORONTO--(MARKET WIRE)--Sep 16, 2005 -- Syneron Medical Ltd. and Syneron North America (NasdaqNM:ELOS - News) today announced that American Laser Centers (ALC) will purchase $6.0 million worth of Syneron equipment for deployment in its centers throughout the nation.

ALC, with more than 100 physician-supervised locations in the U.S., evaluated the VelaSmooth(TM), and decided to expand the activity of its clinics from hair removal and skin rejuvenation also to include cellulite treatment. ALC's new order with Syneron is for the purchase of 100 Syneron platforms with delivery scheduled over the next six months. The order includes both the VelaSmooth and the Aurora(TM) system -- Syneron's flagship product for hair removal and FotoFacial® treatments.

"Syneron is pleased to build on our current relationship with ALC as its exclusive equipment provider at this time of tremendous expansion," said Domenic Serafino, president, Syneron North America. "By working even more closely with a medical chain like ALC, Syneron will achieve greater market awareness for the elos(TM) technology and Syneron's wide portfolio of medical aesthetic platforms."

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative elos(TM) technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/050916/095398.html

Dubi

[midastouch017]

CIBC: Syneron may double expected VelaSmooth sales in the third quarter
15.9.2005 | 21:00
Omri Cohen

On September 12, 2005, American Laser Centers announced its acquisition of Lynnwood, Wash.-based Advanced Laser Clinics, doubling its number of treatment centers and expanding to 31 states around the United States. Why should Israeli investors know? Possibly because American Laser Centers is a client of Syneron (TASE, Nasdaq:ELOS) and the transaction stands to add significantly to the Israeli company's revenues, suggests CIBC.

Syneron could be in line for a big order from the American company, amounting to $5 million or more, for its VelaSmooth anti-cellulite and wrinkle fighting devices.

CIBC also sought to assuage investor concern about the VelaSmooth, which remains Syneron's exclusive property and recently received U.S. marketing approval. There were claims that the device didn't really deliver and that doctors were dissatisfied, and that competition was developing, the analysts recap. Investors shouldn't let those reports deter them, they conclude.

The investment bank reiterated an Outperform investment rating and 12-month price target of $52, compared with its present share price today of $37.40. They foresee potential sales of 125 VelaSmooth units in the third quarter, which is double initial projections.

http://tinyurl.com/9ztgu

Dubi

[midastouch017]

NEW YORK - Aug. 2 was a lackluster day in the trading of high-flying tech stock Syneron Medical. It barely budged, dropping a mere 9 cents to $40.85. After-hours action also looked blasé until 5:33 P.M. EST, when "freedompartner" posted this on Yahoo!: "Cramer said buy ELOS before earnings: Just finished taping the show. He loves ELOS." The message referred to market pundit James Cramer and his wildly successful CNBC show, Mad Money.

Syneron (nasdaq: ELOS - news - people ) began moving higher and trading picked up. That night on Mad Money, which CNBC tapes from 4:30 P.M. to 5:30 P.M. EST and broadcasts from 6:00 P.M. to 7:00 P.M. EST, Cramer indeed touted Syneron's laser products' ability to smooth away cellulite. "I am sticking the proverbial neck out" and telling you to buy ELOS now before earnings, he exclaimed. The stock spiked to $45.46 in after-hours trading on volume of 300,000 shares.

What happened? Apparently someone called Mad Money during taping for the Q&A segment, heard the tout while on hold and disseminated the information on the Web before the show aired, against CNBC's admonition.

A taped recording warns callers that they will hear the show and must agree to not disclose or trade on information discussed prior to that information being mentioned during the during the 6 P.M. airing. "This is extremely important," counsels the recording, "and if you cannot abide by this rule, please hang up now."

Transgressors can, of course, ignore the instructions, remain on the line and spread Cramer's picks. Should that happen, says a CNBC spokesperson, that person "would be banned from participating in all future programs, and the network will consider appropriate legal action based on the specific facts involved."

As it happens, viewers who bought ELOS got burned two days later. Syneron's earnings disappointed, and the stock fell back to its earlier level. On Thursday, it was trading at $36.83.

For two decades, Cramer, 50, has told America what to buy and sell in print (SmartMoney, Time, New York), on the Web (TheStreet.com), on a radio show and now on TV. He also ran a hedge fund, Cramer Berkowitz, that claimed a 24% annual return, after fees, over 15 years. He burned out and retired in 2001.

Since its March debut, Mad Money has become CNBC's second-highest-rated program, in what was previously its lowest-rated time slot (except for the 5 A.M. show), drawing nearly 200,000 viewers five nights per week. The show amounts to Cramer being Cramer--as raw and uncensored as ever. He feverishly bounces around the studio, rants at the camera and bangs on buttons blaring the sound effects of cash registers and bowling pins, growling bears and raging bulls.

He's also spawned a burgeoning subculture of trading types looking to make a quick buck off of his calls. With a flat market and dormant volatility, brokers and traders are desperate for anything that moves stocks, and in Mad Money they've found their Messiah.

Aside from Yahoo!'s (nasdaq: YHOO - news - people ) boards, which are replete with Cramer references, there are at least three independent Web sites devoted to Mad Money. (Cramer's TheStreet.com also devotes substantial coverage to the show.) It's not just chat-roomers paying attention. Brokerages such as Cantor Fitzgerald include Cramer's picks in their research notes, which are distributed to mutual fund and hedge fund clients.

"At first, we didn't cover Mad Money's picks, but our customers kept talking about the show's impact," says Damon Southward of Briefing.com, a news service used by investors that now includes the show's content in its product. "We need to stay on top of volatility, and if there's one thing Cramer creates, it's volatility."

Southward says that while he's seen other commentators affect markets, such as Dan Dorfman, Business Week's Gene Marcial and TV host Louis Rukeyeser--Cramer's show has a more widespread impact.

"Cramer weighs in on dozens of stocks every show," explains Southward. "Increasing the show's effect is a robust after-hours trading market--viewers buy and sell stocks while watching the show."

Earlier in his career, Cramer raised eyebrows as one of the first money managers to write about stocks. In 1995, the SEC investigated whether he broke any laws writing columns about his holdings. Cramer was exonerated, but disclosures and disclaimers were added to his stories. They have followed Cramer ever since, but none as long-winded as Mad Money's. In the show's opening minute, a 263-word disclaimer scrolls down the screen (in a tiny font). Callers are subjected to an even lengthier two-minute disclosure recording.

Despite the cautious measures, it appears CNBC is still grappling with the mysterious ways in which Mad Money moves stocks. On Aug. 8 around noon, CNBC announced on its Web site that Charles Goodson, chief executive of PetroQuest Energy (nasdaq: PQUE - news - people ), was going to be Cramer's guest that evening. PetroQuest promptly surged 7% on four times its average volume. Chief executive appearances are typically positive, and Cramer is bullish on oil stocks.

As it turned out, Mad Money had booked Goodson for the following Monday. Informed by Forbes of the error, the network removed Goodson's name from the Web site and canceled his appearance. It also decided to discontinue posting Mad Money guests on its Web site prior to the show's broadcast.

"CNBC will continue to take steps to ensure that the integrity of the program remains intact," says a CNBC spokesperson.

While it might be able to protect the show's integrity, CNBC can't control whether the show achieves its stated goal--making people money.

Last Monday after a weeklong Hawaiian vacation, a bronzed Cramer returned to CNBC's studios as unhinged as ever. He immediately trumpeted his pick of the week--Dick's Sporting Goods (nyse: DKS - news - people ), the athletic-gear and apparel chain.

"This is the best story you've never heard of," he enthused, urging viewers to buy Dick's ahead of its earnings announcement the next morning.

Although Cramer warned his disciples only to buy with a limit order to prevent the stock's spiking, Dick's popped 7% to $41.93, trading 300,000 shares during Mad Money. By comparison, Cisco Systems (nasdaq: CSCO - news - people ), which traded 60 million shares in Monday's regular session, traded only 12,000 shares between 6 P.M. and 7 P.M.

Tuesday morning, Dick's sliced its 2005 earnings forecast, and the stock tanked, closing down 20% at $32.90.

Enraged, Mad Money viewers flooded Dick's Yahoo! message board with anti-Cramer tirades, many of them--there were over 1,800 posts that day--unsuitable for reprinting on a family Web site.

That evening, Cramer--with an "Eating Crow" graphic prominently displayed behind him--issued a mea culpa, repeating five times "I was wrong." But don't dwell on your mistakes, he exhorted: "Bottom line: You have to move on and get back into the game!"

Many Wall Street watchers don't think it's a game.

"Cramer's moving the markets like the star Internet analysts did during the tech bubble," says Jacob Zamansky, an attorney representing individual investors. "He's got a big following of people who think they're acting responsibly by following Cramer's advice--but in reality he's dangerous to their health."

http://www.forbes.com/2005/08/18/cramer-cnbc-madmoney-cz_pl_0819cramer.html

Dubi

[midastouch017]

What is the name of the company you mentioned recently that has a laser treatment for cellulite?

-- Donnie from Louisiana


James J. Cramer: You are referring to Syneron Medical (ELOS:Nasdaq - commentary - research), which has only been publicly traded for a year. The stock has tripled in that time, and I believe the company remains a good play on health-care spending by the Baby Boomer generation.


http://www.thestreet.com/_yahoo/funds/madmoneymailbag/10237741_2.html

Dubi

[midastouch017]

Lehman Brothers raises forecasts for Syneron
11.8.2005 / 12:35
TheMarker

Lehman Brothers today repeated an Equal Weight rating for Syneron (TASE, Nasdaq:ELOS), after raising its forecasts for the company following its strong second-quarter financial statement.

For the year 2005, analyst Bob Hopkins expects the Israeli medical-laser technology company to report $1.39 earnings per share, up from $1.14 for 2004 and rising to $1.78 in 2006. Compared with his previous estimates, the change upward is about 25%.

His estimates remain below the Wall Street consensus, however.

For the year 2005, Hopkins now estimates Syneron will present $84.3 million in revenue, an increase of $4 million. For the year 2006, he's looking at $110.4 million in recommendation, up $4.7 million from his former projection. Much of the change is due to expected strong sales of the company's cellulite treatment device, Vela, especially from 2006.

Lehman's 12-month price target is $40, based on 23 times estimated 2006 earnings per share of $1.78, Hopkins writes.

Dubi

[midastouch017]

Syneron and EuropeLabs Announce Distribution Agreement for North American Spa Markets
Tuesday August 9, 3:00 pm ET
Syneron elôs(TM) Products to Make Significant Impact on Growing Spa Industry


YOKNEAM, ISRAEL and MONTREAL, CANADA--(MARKET WIRE)--Aug 9, 2005 -- Syneron Medical, Ltd. (NasdaqNM:ELOS - News) announced today that it has selected EuropeLab, Inc.'s Platinum Equipment Division, a leading distributor of cosmetic products and equipment, as its North American distributor for the Dental Spa, Day Spa, Aesthetic and Chiropractic Spa markets.

Under the terms of the agreement, EuropeLabs/Platinum Equipment Division, one of the largest distributors of specialized equipment for the spa market, will now distribute Syneron's VelaSmooth(TM) and the Pitanga(TM) systems to the spa market in North America. The VelaSmooth was recently cleared by the US FDA as an innovative medical device to reduce the appearance of cellulite. The Pitanga is a spa-exclusive machine that provides skin treatments, including the treatment of benign superficial and vascular lesions, and eliminates unwanted hair. Both systems are based on Syneron's elôs(TM) technology, which combines light and bi-polar radio frequencies for the treatment of multiple cosmetic conditions.

"With a client base of more than 4,200 day spas, spas and other aesthetic clinics, Europe Labs/Platinum Equipment has earned the reputation as the leader in 'one-stop-shopping' for top equipment and skincare products to the traditional and emerging spa markets," remarked Daniel Fields, Syneron's Head of New Business Development. "We feel strongly that their goals and capabilities uniquely complement those of Syneron."

"Syneron is the world's fastest growing manufacturer of light-based cosmetic technology. We are pleased that they have looked to EuropeLabs/Platinum Equipment as a strategic partner in their penetration of spa markets," said Manon Pilon, founder, EuropeLabs.

About EuropeLab

EuropeLab is headquartered in Montreal, Canada and is an exclusive supplier of specialized equipment and skin care products to more than 4,200 day spas, spas and other aesthetic clinics throughout North America. In addition to the new line of Syneron products, EuropeLab's brands include: Methode Physiodermie®, a full range of sophisticated and scientifically advanced skin care products from Switzerland, ActivaDerme® an exclusive line of high quality natural nutritional supplements for the skin, and Alaska® products, a full range of spa equipment. Additional information can be found at www.derme.ca, www.platinumequipment.com and www.methodephysiodermie.com

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) manufactures and distributes medical aesthetic devices that are powered by elôs, the combined-energy technology of bi-polar radio frequency and light. The company's innovative elôs technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/050809/092748.html

Dubi

[midastouch017]

To capitalize on Boomer vanity, Cramer urged viewers to consider companies that make lasers for cosmetic surgery, specifically Syneron (ELOS:Nasdaq - commentary - research), Cutera (CUTR:Nasdaq - commentary - research) and Laserscope (LSCP:Nasdaq - commentary - research).

"These three companies pretty much have the market cornered right now," Cramer said, although he warned that they are "all little companies that could be displaced in moments by a bigger player."

http://www.thestreet.com/_yahoo/funds/madmoneywrap/10237122.html?cm_ven=YAHOO&cm_cat=FREE&cm...

Dubi

[midastouch017]

Syneron Medical Reports 2005 Second Quarter Results
Thursday August 4, 7:30 am ET
Company confirms recent increase in revenue guidance to $84-85m for 2005


YOKNEAM, ISRAEL--(MARKET WIRE)--Aug 4, 2005 --
Highlights of second quarter 2005:
-- Total revenues grew over 50%.
-- Over 400 units were sold in the second quarter, raising the world wide
installed base to over 3000 units.
-- FDA cleared the VelaSmooth(TM) and granted the device a new product
code, confirming its unique position in the aesthetic device market.
-- Investment in dental laser market opens new strategic business
opportunities for Syneron.
Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today reported revenues of $20.1 million for its second quarter of 2005, a 50.6% increase from $13.4 million reported in the second quarter of 2004. The increase in revenues was attributable to strong sales across all platforms and the introduction of new platforms: the Comet(TM) system for fast hair removal toward the end of the first quarter of 2005 and the VelaSmooth(TM) system for reduction in the appearance of cellulite at the end of the second quarter of 2005. Gross margins in the second quarter of 2005 were 86.8%. Second quarter operating income grew 40.1% on a proforma basis (excluding expenses for the Thermage settlement) to $8.9 million, from $6.3 million in the second quarter of 2004. Second quarter 2005 net income was $9.2 million proforma, a 43.7% rise compared to the 6.4 million net income reported in Q2 2004. On a US GAAP basis, including the costs of the Thermage settlement, operating income for the second quarter of 2005 was $6.5 million, with net income of $6.9 million. Earnings per diluted share, on a proforma basis for the second quarter of 2005, were $0.34, while on a GAAP basis, earnings per diluted share were $0.25.

R&D expenditure rose to $1.3 million, equivalent to 6.2% of revenues in the second quarter of 2005 compared to $0.5 million, or 3.8% of revenues in the second quarter of 2004. The higher R&D expenditure reflects the continued investment of Syneron in the development of new products and applications, such as non-invasive fat treatment, as well as the expansion of our elos technology product line into applications performed by (non-MD) professionals specializing in aesthetic treatments.

Selling and marketing expenses rose 39.7% to $6.6 million, compared to 4.7 million in Q2 2004. Approximately $0.6 million of the increased selling and marketing expenditures were spent on preparations for the launch of the VelaSmooth, including clinical studies, the establishment of three training centers, development of training courses and promotional and marketing materials.

The Thermage settlement resulted in a one-time charge to Syneron of $2.37 million for legal and settlement expenses. The settlement removed all future legal liabilities or costs to Syneron and gave Syneron a license to relevant Thermage patents, while securing Syneron's exclusive patent rights over its proprietary elos technology.

"Robust sales in the second quarter were driven by a strong sales effort to get the products out to new customers' world wide," commented Moshe Mizrahy, CEO of Syneron. "Sales rose strongly across all markets for Syneron. North America accounted for $12 million, or 59% of total sales, with $8.1, or 41% of sales outside North America. Looking to new future markets, in the second quarter we initiated strategic partnerships in China, India and Russia, with the view of establishing a strong position for Syneron in three emerging markets for aesthetic devices which have enormous growth potential.

"We are confirming the increase in our revenue guidance to $84-85 million from $78-80 million, which we announced on June 30," said Mr. Mizrahy. "This increase in guidance was based on our initial assessment of sales for the Vela, which is showing very strong demand worldwide."

Continuing on Syneron's growth plans, Dr. Shimon Eckhouse, Chairman of Syneron, said, "Our business strategy is driven by an effort to utilize our technologies and market position in new and innovative applications, while maintaining our commitment to the levels of profitability we have obtained as a result of the elos technology. The increase in R&D and the investment in the dental laser venture are the first steps in the evolution of Syneron from a company focused on doctors dealing with aesthetic facial and skin treatments to a company developing products for a broader market base. Our business strategy consists of four central components: strengthening our leadership position in our core business of FotoFacial RF skin treatment; establishing a new segment in the medical aesthetic field for body shaping and body sculpturing treatments; developing a complete product line for the spa and the Non-MD professionals; and developing a complete dental laser line of products through our Light Instruments investment."

Syneron's financial position remains strong. At June 30, 2005, the cash position was $104.5 million compared with $93.4 million on December 31, 2004. Shareholders' equity increased to $110.4 million from $94.4 at year-end 2004.

Conference call

Syneron Management will host a conference call to discuss the results and quarterly highlights at 10:00am ET today, August 4, 2005. Investors and other interested parties may access a live webcast through Syneron's web site at www.syneron.com. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site.
http://biz.yahoo.com/iw/050804/092402.html

Dubi

[midastouch017]

Syneron Medical to Announce Second Quarter Financial Results on August 4, 2005
Thursday July 21, 2:00 pm ET


YOKNEAM, ISRAEL--(MARKET WIRE)--Jul 21, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of ELOS(TM) combined-energy medical aesthetic devices, today announced that it will release its second quarter financial results for the period ending June 30, 2005 on Thursday, August 4, 2005, before market opening. The earnings release will be available on Syneron's website at www.syneron.com.

Dubi

[midastouch017]

Syneron worth $1b

Fidelity Management and Research mutual funds have reached an 11.5% holding in the company.

Tali Tsipori 12 Jul 05 14:37

If you thought that the record levels reached by Syneron Medical Ltd. (Nasdaq:ELOS), a maker of laser medical aesthetic systems for skin treatments, last week would cause shareholders to start selling share, you’d be mistaken, at least for now. Syneron’s share broke another record yesterday, rising 4.3% to $40, reflecting a market cap of $1 billion.
Syneron is now worth three times more than Tadiran Communications Ltd. (TASE:TDCM), which has a turnover of $300 million a year; two times more than Super-Sol Ltd. (TASE:SAE; OTCBB:SSLTF), which has a turnover of $1.3 billion a year; and only $100 million less than Partner Communications Co. Ltd. (Nasdaq: PTNR; TASE:PTNR; LSE:PCCD), which has a turnover of $1 billion a year. Syneron is expected to post $85 million in revenue for 2005.

Apparently, one of the reasons for yesterday’s rise in Syneron’s share price was the fact that Fidelity Management and Research Company mutual funds had reached an 11.5% holding in the company, making the mutual funds the largest shareholders in Syneron. Syneron founder and chairman Dr. Shimon Eckhouse owns 10.7% of the company, and Canadian investment fund Sprott Asset Management Inc. owns 5.6%

Fidelity Management and Research is one of the world’s largest mutual fund management companies. In addition to managing over 300 mutual funds, it offers its customers various financial services, including life insurance and portfolio management. Based in Boston, Fidelity Management and Research is a shareholder in TTI Team Telecom International (Nasdaq: TTIL), Fundtech Ltd. (Nasdaq:FNDT; TASE:FNDT), Ness Technologies Inc. (Nasdaq:NSTC) and other Israeli companies.

Published by Globes [online], Israel business news - www.globes.co.il - on July 12, 2005

Dubi

[midastouch017]

Syneron Announces New Marketing and Communication Appointments
Thursday July 7, 8:00 am ET
Building the Organizational Structure for Future Growth


YOKNEAM, ISRAEL--(MARKET WIRE)--Jul 7, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced four new appointments aimed at reinforcing the Company's global marketing strength and communication channels.

Syneron appointed Stephen May as Global Director of Product Management. Stephen has eight years direct experience in sales and marketing with major aesthetic laser companies, including positions as Senior Product Marketing Manager for Palomar Medical Technologies, Inc. and Director of Marketing for the Aesthetics Division of Lumenis Ltd. (formerly ESC Medical Systems Ltd.). Immediately prior to joining Syneron, Stephen was the Director of Marketing for CDF Corporation, where he achieved a complete re-branding of the company and its legacy product lines and organized a new product line launch. Stephen reports to Dominic Serafino, President of Syneron North America, and Moshe Mizrahy, CEO, Syneron Medical Ltd.

In Europe, the Company appointed Dov Galvin as General Manager, Syneron GmbH. Dov reports to Han Edel, President of Syneron Europe.

In the Asia-Pacific region, Syneron appointed Emily Choy as Asia-Pacific Product Manager and John Knight as Japanese Country Manager. Both Emily and John report to Tom Goslau, Managing Director for Asia-Pacific.

The company promoted Judith Kleinman from Director of Investor Relations to Vice President of Investor Relations. Judith worked as an equity analyst and institutional salesperson for 16 years in London and Tel Aviv. In 1998, Judith opened the UBS Securities office in Tel Aviv, the first foreign broker to obtain a seat on the Tel Aviv Stock Exchange. Judith reports to Moshe Mizrahy.

"We believe we have found the most experienced individuals to fulfill global and regional positions which are of strategic importance to Syneron's continued development and growth," commented CEO Moshe Mizrahy. "We welcome them to Syneron and look forward to the support they will give to our global management team."

http://biz.yahoo.com/iw/050707/090249.html

Dubi

[midastouch017]

Syneron Invests in New Dental Laser Venture
Tuesday July 5, 8:00 am ET
Investment Complements elos(TM) Platform of Aesthetic Medical Devices

YOKNEAM, ISRAEL--(MARKET WIRE)--Jul 5, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced that it has signed an agreement to invest $1.5m in Light Instruments Ltd., an Israeli start-up specializing in the development of advanced dental laser devices.

Syneron's investment, to buy 51% of the new company, will be made in two equal $750,000 tranches. Syneron will fund the second half of the investment only if a prototype of the laser system meets certain technical and clinical specifications. Syneron will also have an option to invest an additional $2m in the company. As part of the investment agreement, Syneron will have exclusive North American marketing and sales rights for 10 years following FDA clearance.

Chairman of Syneron, Dr. Shimon Eckhouse, explained that "dental laser products have many synergies in their technology, manufacture and marketing with Syneron's platform of aesthetic medical devices and the expected margins of the Light Instrument dental system are consistent with the margins of our core products."

Commenting on the market for the dental laser system, Dr. Eckhouse added: "There is a potential market of some 200,000 dentists in North America alone. The dynamics of the dental market have many similarities to the dynamics of the market for aesthetic medical devices in which Syneron is gaining a clear leadership position. Moreover, within the context of private dental clinics and emerging 'dental spas,' dentists are also potential customers for Syneron's core platform of aesthetic medical devices."

http://biz.yahoo.com/iw/050705/090129.html

Dubi

[midastouch017]

Israeli device hides cellulite, re-contours skin's surface
By David Brinn July 03, 2005

Texas resident Shanan Brown spent her first 30 years in a normal weight range and kept her body trim. Then she had two children, and cellulite moved in.

"All of a sudden, it was 'Oh my gosh, this is a big difference,' " Brown, a saleswoman, told the Dallas Morning Herald. "How the heck am I going to get rid of this?"

Working out and dieting didn't do the trick for Brown, 34. It wasn't until her doctor offered to put her into a clinical test of an Israeli-developed device called the VelaSmooth that she saw immediate results.

"It was amazing," she said. "It significantly reduced my cellulite. And I dropped two pants sizes."

Soon, cellulite sufferers throughout the US will be able to take advantage of the VelaSmooth's ability to reduce the appearance of cellulite and safely and effectively re-contour the skin's surface and body shape. Its makers - Syneron - announced last month that the VelaSmooth had received FDA marketing clearance for the temporary reduction in the appearance of cellulite, and for the relief of minor muscle aches, pain and spasm and the temporary improvement of local blood circulation.

Cellulite refers to fat that bulges under the skin. When skin and the fibers connecting the skin to layers of fat underneath weaken, fat cells can rise to the surface. That creates a lumpy look often indelicately compared to cottage cheese.

According to Syneron's Dr. Amir Waldman, the clearance of the VelaSmooth offers a new non-surgical, no downtime alternative for patients wishing to treat the appearance of cellulite, and its launch marks a new era in the medical treatment of cellulite.

The device features Syneron's patented 'elos' technology - 'electrical optical synergy' - which combines two sources of energy - infrared light and radio frequency - with rollers that manipulate the tissue. This combination sends heat into the tissue more deeply than existing treatments to help break down fat within cells and shrink the cells.

"The VelaSmooth is the only device that combines four different methodologies - two heating components, infrared and conducted RF current, a vacuum charger and mechanical manipulation of the skin. All are applied simultaneously in order to get the optimal effect," he told ISRAEL21c.

"There are some massage units for cellulite on the market, and there are also some that use heat lamps and infrared light for a variety of indications. But there's virtually no device that combines all four. This technical superiority is what makes it so effective," explained Waldman, the company's Vice President for Business and Applications, and the overseer of VelaSmooth's clinical testing.

"Trials were conducted at over 100 sites - primarily in the US and Canada, but also in Israel, Europe and Japan. In all, over 500 people were tested with the VelaSmooth - 100% of the patients achieved positive results, some more than others. The two major indicators were cellulite improvement and the reduction of the waist circumference and diameter of the thighs," said Waldman.

Dr. Mary Lee Amerian , a dermatologist in Los Angeles who has participated in the clinical trials of VelaSmooth, told The Los Angeles Times that her patients all showed positive results.

One controlled clinical trial of 20 patients showed that all had some improvement in the appearance of cellulite, and 75 percent had a reduction in the circumference of the treated thigh, with an average reduction of one inch.

Patients typically undergo 45-minute treatments twice a week for about six weeks. Any improvement from the initial series of treatments tends to last about six months, Amerian said. Monthly treatments are needed to maintain the benefits. Most people do not find the treatments painful, she says.

"You also have the mechanical action of the rollers that kneads the skin. It kind of massages it and facilitates penetration of the heat," she said.

VelaSmooth, which costs about $200 a treatment, is an improvement over massage-only techniques, says Dr. Tina S. Alster, the founding director of the Washington Institute of Dermatologic Laser Surgery in Washington, who also conducted clinical trials on the device.

"There has never been a viable treatment for cellulite which is disappointing given the fact that 80 percent of women are affected by it, and the other 20% think they have it. I am now convinced that we have a viable treatment for this condition," she said.

"In our clinical study of 20 women of various ages and skin types with moderate thigh and buttock cellulite, significant clinical improvement was observed in skin contour irregularities, and thigh circumferences were also reduced. Patients didn't lose weight, but they looked as if they had. Our research has shown that it is no longer necessary to endure painful and lengthy recovery times or be exposed to general anesthesia that is typical of other procedures like liposuction in order to achieve improvement of cellulite."

According to Waldman, the FDA created a new product code for the VelaSmooth, confirming its unique position in the aesthetic device market.

"The FDA's designation of a new product category specifically for the VelaSmooth reaffirms how technically innovative this device is for the treatment of cellulite," he said.

Waldman stressed that the VelaSmooth is not meant for home use and because of the energy level of the device, the treatments must be performed or supervised by a doctor.

"It's cleared as a medical device - and will be purchased by physicians for use in clinics; it's not a home use device," he said.

The Velasmooth is just the latest in a line of six platforms Syneron has developed using their elos technology which provide solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, and leg veins.

Founded in 2000, Syneron is headquartered in the Northern Israeli town of Yokneam, and has offices and distributors throughout the world including North American headquarters in Canada and European headquarters in Germany.

But all Shanan Brown in Texas cares about is that her unsightly cellulite can be controlled. And for that, she has Synernon and VelaSmooth to thank.

http://tinyurl.com/bhd9q

Dubi

[midastouch017]

Syneron raises full-year and Q2 revenue forecasts
By YIGAL GRAYEFF

Syneron Medical has raised its full-year revenue forecast to between $84 million and $85m. from a previous estimate of $78m. to $80m. following premarket clearance from the US Food and Drug Administration for its VelaSmooth cellulite treatment.

Should the company meet its forecast, sales will have grown 38 percent from the $57.9 million it earned in 2004. Syneron also increased its predictions for the second quarter to $20m. from $18m.-$19m. compared with $13.7m. in the same period a year earlier.

The company said on Monday that it received clearance to use VelaSmooth for the relief of minor muscle aches, pain and spasm and the temporary improvement of local blood circulation, as well as for the temporary reduction in the appearance of cellulite.

VelaSmooth uses non-surgical techniques to heat and manipulate cellulite, said Dr. Tina Alster, director of the Washington Institute of Dermatologic Laser Surgery.

Despite the increase in its forecast, Syneron's shares were down 1.6% at $37.30 in midmorning trading on Nasdaq, although they were 70% up on last Friday's close of $37.30.

http://www.jpost.com/servlet/Satellite?pagename=JPost/JPArticle/ShowFull&cid=1120184358794

Dubi

[midastouch017]

Syneron Raises Revenue Guidance
Thursday June 30, 8:00 am ET


YOKNEAM, ISRAEL--(MARKET WIRE)--Jun 30, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced that following receipt of the FDA's 510(k) pre-market clearance for its VelaSmooth(TM) cellulite treatment system and a preliminary assessment of market demand, it is raising revenue guidance for Q2 2005 to $20m from its prior estimate of $18-19m. The Company is increasing revenue guidance for the year to $84-85m from a previous range of $78-80m.
Commenting on the revenue guidance revision, CEO of Syneron, Moshe Mizrahy, said, "Initial market response to the VelaSmooth has been very positive. We have a strong marketing program underway for the Vela, including clinical training programs, and we expect to receive strong orders in the second half of the year."

http://biz.yahoo.com/iw/050630/089795.html

Dubi

[midastouch017]

Syneron Announces Additional Regulatory Clearances in Q2 2005
Tuesday June 28, 8:30 am ET
Rate of Regulatory Clearances Worldwide for elos(TM) Products Continues Strongly


YOKNEAM, ISRAEL and TORONTO--(MARKET WIRE)--Jun 28, 2005 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) announced that during Q2 2005 it received FDA clearances for two new Syneron applicators and was also granted additional regulatory clearances in several other markets.


The FDA cleared Syneron's new Aurora(TM) SR advanced applicator with broader specifications to treat superficial benign vascular and pigmented lesions. The FDA also granted clearance for Syneron's new advanced Aurora DS applicator with broader specifications for permanent hair reduction treatment. Both new applicators have been designed for use on the Aurora and Galaxy(TM) platforms.

Since March, Syneron has added three new regulatory clearances for the VelaSmooth(TM) system: Australia, Korea, and the Philippines. These new Asia-Pacific clearances follow regulatory clearances in the U.S., Canada, and Europe for the VelaSmooth, Syneron's medical device for the treatment of cellulite.

In Europe, Syneron received Medical CE Mark approval for its Comet(TM) high-speed hair removal system.

According to Syneron's head of regulatory and clinical affairs, Dr. Amir Waldman, "Syneron continues to strengthen its global leadership position with new product development and enhancements to our existing successful product offering. The momentum of clearances from regulatory authorities worldwide is testimony to the safety and efficacy of Syneron products and the elos(TM) technology on which they are based."

http://biz.yahoo.com/iw/050628/089690.html

Dubi